Syndax Pharma (SNDX) Stock Price, Quote & News

Company Profile

Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory R/R acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease. The company is also developing revumenib for the treatment of R/R acute myeloid leukemia (AML) with a n...

Industry: Biotechnology

Sector: Healthcare

Phone: 781 419 1400

Website: syndax.com

Address:

730 Third Avenue, 9th Floor, New York, United States

JFais Apr. 4 at 4:00 PM

$SNDX (L) From Weekly Recap

0 · Reply

Night_Owl_Biotech Apr. 3 at 5:36 PM

The attachment notes the 22 commercial-stage bios trading within 10% of their highest closing share price since 12/1/2025 as of 4/2/2026. We count 89 such bios in total in this peer group (25 oncology focused with MCs over $300MM & 64 non-oncology focused with MCs over $800MM). $RPRX $KNSA $AGIO & $TGTX are the non-oncology bios in this peer group all trading at their highest share prices since 12/1/2025. $SNDX closed at its highest closing price in oncology. Thank you Goldman Sachs. SNDX investors may want to look at SNDX trading after Goldman's last upgrade that, our records reflect, was issued on 9/5/25. This is not investment advice.

1 · Reply

Burning_Cash Apr. 3 at 12:57 PM

$SNDX Up 95% over the past 12 months. Not too shabby. And not the end of it. Laughably low number of watchers. Investors are sure sleeping on this gem.

0 · Reply

WallStreetBuyDip Apr. 3 at 5:56 AM

$SNDX Trading at $25.15, similar to recent levels. Average volume is 2.1M, calmer than the past few days.

0 · Reply

flanker30 Apr. 3 at 1:47 AM

$SNDX if a BO happens soon (hopefully), are we still looking around $42-45 BO price?!

1 · Reply

PennyPoacher Apr. 2 at 11:16 PM

$SNDX

0 · Reply

RonIsWrong Apr. 2 at 8:36 PM

$SNDX finally closed above $25.

0 · Reply

HLR78613 Apr. 2 at 8:18 PM

$SNDX great investment. I also believe this is a near term BO stock.

0 · Reply

BioRich Apr. 2 at 7:45 PM

$SNDX Love this stock/company/pipeline/future. Been sitting on my Buyout back burner list for awhile now, but feels like we're close. If nothing else, we've had a nice SP run for the past year and don't see it ending anytime soon. Doubled my position today at $25.20. Fine if it dips because I see where this is going. Follow/Subscribe for more suggestions and perspective. Would love to hear yours too. That's how we find these gems and learn. Let's make some (more) money. Cheers!

2 · Reply

Burning_Cash Apr. 2 at 7:40 PM

$SNDX

0 · Reply

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Mar 18, 2026, 2:12 PM EDT - 17 days ago

Syndax Pharma: Two Drug Launches Fuel Transformational Growth

Mar 12, 2026, 2:22 PM EDT - 23 days ago

Syndax Pharmaceuticals, Inc. (SNDX) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Feb 26, 2026, 10:47 PM EST - 5 weeks ago

Syndax Pharmaceuticals, Inc. (SNDX) Q4 2025 Earnings Call Transcript

Feb 26, 2026, 4:01 PM EST - 5 weeks ago

Syndax Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Feb 23, 2026, 7:00 AM EST - 5 weeks ago

Syndax Announces Participation in March Investor Conferences

Feb 19, 2026, 7:00 AM EST - 6 weeks ago

Syndax to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call and Webcast on February 26, 2026

Feb 12, 2026, 5:44 AM EST - 7 weeks ago

Syndax Pharmaceuticals' Early Launch Success Signals Continued Growth Into 2026

Feb 5, 2026, 7:00 AM EST - 2 months ago

Syndax Announces Participation at the 2026 Guggenheim Emerging Outlook: Biotech Summit

Jan 13, 2026, 1:25 AM EST - 2 months ago

Syndax Pharmaceuticals, Inc. (SNDX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 12, 2026, 7:00 AM EST - 2 months ago

Syndax Reports Preliminary 2025 Financial Highlights and Provides Business Updates at the 44th Annual J.P. Morgan Healthcare Conference

Jan 7, 2026, 7:00 AM EST - 3 months ago

Syndax and World Orphan Drug Alliance to Launch a Multi-Regional Managed Access Program, Expanding Access to Revuforj® (revumenib) Outside the U.S.

Jan 5, 2026, 7:00 AM EST - 3 months ago

Syndax Announces Presentation at the 44th Annual J.P. Morgan Healthcare Conference

Dec 17, 2025, 8:15 AM EST - 3 months ago

Syndax Pharma: Continuing Execution In AML

Dec 12, 2025, 7:00 AM EST - 4 months ago

Revuforj® (revumenib) Named Best New Drug at the Scrip Awards 2025

Dec 8, 2025, 6:47 PM EST - 4 months ago

Syndax Pharmaceuticals, Inc. (SNDX) Presents at The 67th American Society of Hematology (ASH) Annual Meeting Transcript

Dec 8, 2025, 6:50 AM EST - 4 months ago

Syndax Highlights Leadership in Menin Inhibition at ASH 2025 with Multiple Revuforj® (revumenib) Presentations Spanning the Acute Leukemia Treatment Continuum

Dec 1, 2025, 7:00 AM EST - 4 months ago

Syndax Announces Participation at the 8th Annual Evercore Healthcare Conference

Nov 29, 2025, 10:08 PM EST - 4 months ago

Syndax: Early Commercial Momentum Points Toward Strong 2026 Growth

Nov 10, 2025, 2:01 PM EST - 5 months ago

Syndax Pharmaceuticals, Inc. (SNDX) Presents at UBS Global Healthcare Conference 2025 Transcript

Nov 5, 2025, 11:57 AM EST - 5 months ago

Syndax Pharmaceuticals: Thesis Firing On All Cylinders, Sales Acceleration In 2026

Nov 3, 2025, 9:06 PM EST - 5 months ago

Syndax Pharmaceuticals, Inc. (SNDX) Q3 2025 Earnings Call Transcript

Nov 3, 2025, 4:01 PM EST - 5 months ago

Syndax Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov 3, 2025, 9:08 AM EST - 5 months ago

Syndax Announces Compelling Revuforj® (revumenib) and Niktimvo™ (axatilimab-csfr) Data Accepted for Presentation at ASH 2025

Nov 3, 2025, 9:08 AM EST - 5 months ago

Syndax to Host ASH Investor Event in Person and via Webcast on December 8, 2025

Oct 30, 2025, 7:00 AM EDT - 5 months ago

Syndax Announces Participation in November Investor Conferences

Oct 27, 2025, 7:00 AM EDT - 5 months ago

Syndax to Announce Third Quarter 2025 Financial Results and Host Conference Call and Webcast on November 3, 2025

Oct 26, 2025, 11:44 PM EDT - 5 months ago

Syndax Expands Revuforj Approval, Buy

$Syndax Pharmaceuticals, Inc. (SNDX) Discusses FDA Approval of Revuforj for Relapsed or Refractory NPM1 Mutated Acute Myeloid Leukemia Transcript$

Oct 24, 2025, 8:47 PM EDT - 5 months ago

Syndax Pharmaceuticals, Inc. (SNDX) Discusses FDA Approval of Revuforj for Relapsed or Refractory NPM1 Mutated Acute Myeloid Leukemia Transcript

$Syndax Announces FDA Approval of Revuforj® (revumenib) in Adult and Pediatric Patients with Relapsed or Refractory NPM1 Mutated Acute Myeloid Leukemia$

Oct 24, 2025, 1:58 PM EDT - 5 months ago

Syndax Announces FDA Approval of Revuforj® (revumenib) in Adult and Pediatric Patients with Relapsed or Refractory NPM1 Mutated Acute Myeloid Leukemia

Oct 15, 2025, 2:30 PM EDT - 6 months ago

3 Biotech Stocks I Am Accumulating

ADMA HRMY INCY XBI

Oct 9, 2025, 5:00 PM EDT - 6 months ago

Making Money In Biotech Stocks

GERN

Sep 19, 2025, 12:53 PM EDT - 7 months ago

3 Potential Biotech Acquisition Targets

AZN ETNB INCY MLYS TVTX

$Syndax's Revuforj® (revumenib) Included in NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for the Treatment of Relapsed or Refractory NPM1 Mutated Acute Myeloid Leukemia$

Sep 19, 2025, 7:00 AM EDT - 7 months ago

Syndax's Revuforj® (revumenib) Included in NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for the Treatment of Relapsed or Refractory NPM1 Mutated Acute Myeloid Leukemia

Sep 10, 2025, 6:10 PM EDT - 7 months ago

Syndax Pharmaceuticals: Revumenib PDUFA Review mNPM1 AML And Move Towards MSS CRC

Sep 2, 2025, 7:50 PM EDT - 7 months ago

Syndax Pharmaceuticals, Inc. (SNDX) Presents At Citi's Biopharma Back To School Conference Transcript

Aug 26, 2025, 7:00 AM EDT - 7 months ago

Syndax Announces Participation in September Investor Conferences

Aug 13, 2025, 6:34 PM EDT - 8 months ago

Syndax Pharmaceuticals: A Tale Of Two Drug Launches

Aug 5, 2025, 12:59 PM EDT - 8 months ago

Syndax Pharmaceuticals: The Story Brightens

Aug 4, 2025, 11:52 PM EDT - 8 months ago

Syndax Pharmaceuticals, Inc. (SNDX) Q2 2025 Earnings Call Transcript

Aug 4, 2025, 4:01 PM EDT - 8 months ago

Syndax Reports Second Quarter 2025 Financial Results and Provides Business Update

Jul 28, 2025, 7:00 AM EDT - 8 months ago

Syndax to Announce Second Quarter 2025 Financial Results and Host Conference Call and Webcast on August 4, 2025

Jul 8, 2025, 5:18 AM EDT - 9 months ago

Syndax Pharmaceuticals: Oversold Pharma Likely To Benefit From Drug Approvals

$Syndax Announces FDA Priority Review of sNDA for Revuforj® (revumenib) in Relapsed or Refractory mNPM1 Acute Myeloid Leukemia$

Jun 24, 2025, 4:01 PM EDT - 10 months ago

Syndax Announces FDA Priority Review of sNDA for Revuforj® (revumenib) in Relapsed or Refractory mNPM1 Acute Myeloid Leukemia

Jun 12, 2025, 12:02 PM EDT - 10 months ago

Syndax Announces Publication of Revumenib Data from the BEAT AML Trial in the Journal of Clinical Oncology and Simultaneous Presentation at EHA 2025

$Syndax Presents New Revuforj® (revumenib) Data in Relapsed/Refractory mNPM1 and NUP98r Acute Leukemia from AUGMENT-101 Trial at EHA 2025$

Jun 12, 2025, 7:00 AM EDT - 10 months ago

Syndax Presents New Revuforj® (revumenib) Data in Relapsed/Refractory mNPM1 and NUP98r Acute Leukemia from AUGMENT-101 Trial at EHA 2025

May 29, 2025, 7:00 AM EDT - 11 months ago

Syndax Announces Participation in June Investor Conferences

May 14, 2025, 9:30 AM EDT - 11 months ago

Syndax Announces Data Presentations at EHA 2025 Showcasing Revuforj® (revumenib) and Niktimvo™ (axatilimab-csfr)

May 12, 2025, 4:01 PM EDT - 11 months ago

Syndax Pharmaceuticals Appoints Dr. Nicholas Botwood as Head of Research and Development and Chief Medical Officer

May 8, 2025, 7:00 AM EDT - 11 months ago

Syndax Announces Participation in May Investor Conferences

JFais Apr. 4 at 4:00 PM

$SNDX (L) From Weekly Recap

0 · Reply

Night_Owl_Biotech Apr. 3 at 5:36 PM

1 · Reply

Burning_Cash Apr. 3 at 12:57 PM

$SNDX Up 95% over the past 12 months. Not too shabby. And not the end of it. Laughably low number of watchers. Investors are sure sleeping on this gem.

0 · Reply

WallStreetBuyDip Apr. 3 at 5:56 AM

$SNDX Trading at $25.15, similar to recent levels. Average volume is 2.1M, calmer than the past few days.

0 · Reply

flanker30 Apr. 3 at 1:47 AM

$SNDX if a BO happens soon (hopefully), are we still looking around $42-45 BO price?!

1 · Reply

PennyPoacher Apr. 2 at 11:16 PM

$SNDX

0 · Reply

RonIsWrong Apr. 2 at 8:36 PM

$SNDX finally closed above $25.

0 · Reply

HLR78613 Apr. 2 at 8:18 PM

$SNDX great investment. I also believe this is a near term BO stock.

0 · Reply

BioRich Apr. 2 at 7:45 PM

2 · Reply

Burning_Cash Apr. 2 at 7:40 PM

$SNDX

0 · Reply

Kingjake26 Apr. 2 at 7:01 PM

$SNDX nice :)

2 · Reply

buylowandwait Apr. 2 at 6:47 PM

$SNDX One of the best value in bio right now. The existing drug on market will propel the company into profitability. The pipeline is stellar with huge potential. M&A will probably fetch 50/share....

1 · Reply

Georgeson Apr. 2 at 4:35 PM

$SNDX Now watch it go straight up after I sold. Thank me later. 😀

1 · Reply

Georgeson Apr. 2 at 4:08 PM

$SNDX IMO, seeing and guessing where the wind is blowing re silly war in Iran is just if not more important than knowing and watching a stock's fundamentals. Thus I sold a big chunk of my sndx holdings today at $24.75.

0 · Reply

DragonAlgo Apr. 2 at 3:53 AM

🐉 $SNDX CALL — DragonAlgo® Signal Contract: SNDX CALL Expiry: 2026-04-17 | Strike: $10.00 | Type: CALL Option Plan (premium): Entry: $13.40 Stop: $9.65 TP1: $17.42 TP2: $22.78 TP3: $32.16 🔗 https://dragonalgo.com

0 · Reply

Theobviouschoice Apr. 1 at 11:21 PM

$SNDX Now we're talking - AH trade $8.1M

1 · Reply

RonIsWrong Apr. 1 at 7:21 PM

$SNDX price reaction to GS PT increase

1 · Reply

erevnon Apr. 1 at 6:29 PM

Goldman Sachs maintains Syndax Pharmaceuticals $SNDX at Buy and raises the price target from $28 to https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

TrudeWebster Apr. 1 at 6:19 PM

$SNDX Goldman Sachs Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating, Raises Target Price to $34

0 · Reply

DragonAlgo Apr. 1 at 11:26 AM

🐉 $SNDX PUT — DragonAlgo® Signal Contract: SNDX PUT Expiry: 2026-04-17 | Strike: $23.00 | Type: PUT Option Plan (premium): Entry: $1.06 Stop: $0.76 TP1: $1.38 TP2: $1.80 TP3: $2.54 🔗 https://dragonalgo.com

0 · Reply

Georgeson Apr. 1 at 3:36 AM

$SNDX Today's volume was about 2x avg 3 month volume. Interesting.

2 · Reply

Jarvis7424 Apr. 1 at 12:15 AM

$SNDX I’ll take a BO for $40+

0 · Reply

Market Cap	2.22B
Revenue (ttm)	172.35M
Net Income (ttm)	-285.42M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-165.60%
Debt to Equity Ratio	5.32

Volume	2,093,700
Avg Vol	1,416,572
Day's Range	N/A - N/A
Shares Out	88.20M
Stochastic %K	86%
Beta	0.41
Analysts	Strong Sell
Price Target	$39.33